<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640534</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 08/14 - IMPROVE</org_study_id>
    <nct_id>NCT02640534</nct_id>
  </id_info>
  <brief_title>Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone</brief_title>
  <official_title>Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test if the combination of enzalutamide and metformin in
      patients with castration resistant prostate cancer CRPC progressing on androgen deprivation
      therapy ADT is more effective compared to enzalutamide alone. The half of the patients will
      receive the experimental treatment combination, enzalutamide and metformin, while the other
      half will receive enzalutamide alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One in seven men will be diagnosed with cancer of the prostate during his lifetime .
      Accordingly, prostate cancer (PC) is the most common cancer amongst men in the western world
      and worldwide. PC ranks second in cancer incidence and sixth in cancer mortality in men. The
      current standard of care for patients with metastatic castration resistant prostate cancer
      (mCRPC) and disease progression is either treatment with abiraterone acetate and prednisone
      in asymptomatic or mildly symptomatic patients without visceral metastases, or treatment with
      docetaxel in more symptomatic patients and in the presence of visceral metastases.

      Rothemundt et al. previously demonstrated favorable effects of metformin in a phase II trial:
      it yields objective Prostate specific antigen PSA responses and may induce disease
      stabilization and improve metabolic endpoints in patients with CRPC. Therefore addition of
      metformin to enzalutamide might have positive impact on tumor progression, on body
      composition, and insulin sensitivity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2016</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control (DC)</measure>
    <time_frame>at 15 months</time_frame>
    <description>The primary endpoint of the trial is disease control (DC) at 15 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response (OR)</measure>
    <time_frame>at 15 months</time_frame>
    <description>Overall response (OR) according to modified RECIST and PCWG2 recommendations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>at 15 months</time_frame>
    <description>EFS is defined as the time from randomization until progression or death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>at 15 months</time_frame>
    <description>AEs will be assessed according to NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 15 months</time_frame>
    <description>OS will be calculated from randomization until death due any reason.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Cancer of the Prostate</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Enzalutamide + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzalutamide 160 mg od + metformin 850 mg bid until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enzalutamide 160 mg od until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide 160 mg od until disease progression</description>
    <arm_group_label>Enzalutamide + Metformin</arm_group_label>
    <arm_group_label>Enzalutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850 mg bid until disease progression</description>
    <arm_group_label>Enzalutamide + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to ICH/GCP regulations before registration and
             prior to any trial-related investigations

          -  Histologically or cytological confirmed adenocarcinoma of the prostate without small
             cell carcinoma or small cell components

          -  Asymptomatic or minimally symptomatic patients in relation to disease

          -  Metastatic adenocarcinoma of the prostate documented by imaging (CT/MRI and/or bone
             scan)

          -  Ongoing androgen deprivation therapy with Gonadotropin-releasing hormone GnRH
             analogues or bilateral orchiectomy (i.e. surgical or medical castration)

          -  Total testosterone levels ≤ 1.7 nmol/L (corresponding to ≤ 50 ng/dL)

          -  Tumor progression at the time of registration, defined as per protocol.

          -  Completed baseline QoL and pain questionnaires

          -  Male patients ≥ 18 years

          -  WHO performance status 0-2

          -  Adequate hematologic values: hemoglobin ≥ 90 g/L, neutrophils ≥ 1.0 x 109/L, platelets
             ≥ 75 x 109/L

          -  Adequate hepatic function: ALT and AST ≤ 2.5 x ULN, bilirubin ≤ 1.5 x ULN (exception
             if Gilbert's syndrome ≤ 2.5 x ULN)

          -  Adequate renal function: calculated creatinine clearance ≥ 50 mL/min, according to the
             formula of Cockcroft-Gault

          -  Patient is able to swallow the trial drugs and comply with trial requirements

          -  Patient agrees not to father a child during participation in the trial and during 3
             months thereafter

          -  Patient agrees to participate to the mandatory translational research part of the
             trial with exception of Pyruvate dehydrogenase sub-study.

        Exclusion Criteria:

          -  Known or suspected Central nervous system CNS metastases or active leptomeningeal
             disease

          -  Previous malignancy within 2 years prior to registration, with the exception of
             localized non-melanoma skin cancer and Ta and Tis bladder cancer

          -  Prior treatment for prostate cancer with

               -  novel endocrine agents (including abiraterone acetate, enzalutamide, TAK-700,
                  TAK-683, TAK-448, VT464, ODM201, ARN509),

               -  radioisotopes,

               -  TKI and other small molecules,

               -  immunotherapy,

               -  chemotherapy (with the exception of docetaxel chemotherapy in hormone sensitive
                  prostate cancer)

          -  Treatment with experimental drugs or treatment within a clinical trial within 30 days
             prior to registration (except the clinical trial SAKK 96/12 and/or the biobank project
             SAKK 63/12)

          -  Clinically significant cardiovascular disease including:

               -  Myocardial infarction within 6 months prior to registration,

               -  Uncontrolled angina within 3 months prior to registration,

               -  Congestive heart failure NYHA class III or IV,

               -  QTc interval &gt; 480 ms,

               -  History of clinically significant ventricular arrhythmias (e.g. ventricular
                  tachycardia, ventricular fibrillation, torsades de pointes),

               -  History of Mobitz II second or third degree heart block without a permanent
                  pacemaker in place,

               -  Uncontrolled hypertension as indicated by systolic blood pressure &gt; 170 mmHg OR
                  diastolic blood pressure &gt; 105 mmHg

          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the
             investigator, would make the patient inappropriate for enrollment (e.g. uncontrolled
             or acute severe infection, advanced chronic obstructive pulmonary disease, heart
             failure)

          -  Known history of HIV, hepatitis B, hepatitis C

          -  Major surgery within 4 weeks prior to registration

          -  Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer
             disease within 3 months prior to registration)

          -  Treatment with metformin within the last 6 months prior to registration

          -  Patients on pharmacotherapy for diabetes mellitus

          -  History of diabetic ketoacidosis, diabetic coma and pre-coma

          -  Known history of seizures or any conditions that may predispose to seizure. History of
             loss of consciousness or transient ischemic attack within 12 months prior to
             registration

          -  Concurrent anticoagulation with rivaroxaban or warfarin

          -  Known hypersensitivity to the IMPs or hypersensitivity to any of their components

          -  Any concomitant drugs contraindicated for use with the IMPs according to the
             Swissmedic approved product information

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the trial protocol and follow-up.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Rothermundt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Schneider</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Wehrhahn, Dr. med.</last_name>
      <phone>+41 62 838 60 50</phone>
      <email>tobias.wehrhahn@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Tobias Wehrhahn, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Rothschild, MD</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>sacha.rothschild@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Sacha Rothschild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Roggero, MD</last_name>
      <email>roggero@ticino.com</email>
    </contact>
    <investigator>
      <last_name>Enrico Roggero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Cathomas, MD</last_name>
      <phone>+41 81 256 66 95</phone>
      <email>richard.cathomas@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Richard Cathomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Thurgau AG</name>
      <address>
        <city>Frauenfeld</city>
        <zip>CH-8500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Woelkly, MD</last_name>
      <phone>+41 52 723 76 91</phone>
      <email>regina.woelkly@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Regina Woelkly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Patrikidou, MD</last_name>
      <phone>+41 79 553 60 99</phone>
      <email>anna.patrikidou@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Anna Patrikidou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCAC Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bohanes, MD</last_name>
      <phone>+41 (21) 646 79 94</phone>
      <email>pbohanes@bluewin.ch</email>
    </contact>
    <investigator>
      <last_name>Pierre Bohanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern 16</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beat Müller, MD</last_name>
      <phone>+41 41 205 58 60</phone>
      <email>beat.mueller@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Beat Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais</name>
      <address>
        <city>Martigny</city>
        <zip>1920</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Anchisi, MD</last_name>
      <phone>+41 27 603 90 00</phone>
      <email>sandro.anchisi@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Sandro Anchisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Mingrone, MD</last_name>
      <phone>41-62-311-4241</phone>
      <email>wmingrone_ol@spital.ktso.ch</email>
    </contact>
    <investigator>
      <last_name>Walter Mingrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Anchisi, MD</last_name>
      <phone>+41 27 603 45 00</phone>
      <email>sandro.anchisi@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Sandro Anchisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bürgerspital Solothurn</name>
      <address>
        <city>Solothurn</city>
        <zip>CH-4500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe von Burg, MD</last_name>
      <phone>+41 32 627 47 00</phone>
      <email>philippe.vonburg@spital.so.ch</email>
    </contact>
    <investigator>
      <last_name>Philippe von Burg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Rothermundt, MD</last_name>
      <phone>+41 71 494 11 63</phone>
      <email>christian.rothermundt@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Rothermundt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Fischer, MD</last_name>
      <phone>+41 052 266 40 87</phone>
      <email>natalie.fischer@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Natalie Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Marek, Dr. med.</last_name>
      <phone>+41 (44) 466 11 11</phone>
      <email>aleksandra.marek@triemli.zuerich.ch</email>
    </contact>
    <investigator>
      <last_name>Aleksandra Marek, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hermanns, MD</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>thomas.hermanns@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Hermanns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Cancer of the prostate</keyword>
  <keyword>Metformin</keyword>
  <keyword>Enzalutamide</keyword>
  <keyword>Xtandi</keyword>
  <keyword>castration resistant prostate cancer</keyword>
  <keyword>phase II</keyword>
  <keyword>Androgen deprivation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

